Cell Therapy Market to Reach $48B by 2033, Fueled by CAR-T Expansion, Chronic Disease Burden, Precision Medicine Demand

DataM Intelligence forecasts 21.4% CAGR as next-gen cell therapies reshape oncology, autoimmune, and regenerative care across global markets.

LOS ANGELES, CA, UNITED STATES, July 31, 2025 /EINPresswire.com/ -- The Cell Therapy Market size was valued at US$ 6.52 billion in 2024 and is projected to grow significantly, reaching approximately US$ 48.98 billion by 2033. This represents a robust compound annual growth rate (CAGR) of 21.4% over the forecast period from 2025 to 2033.

Download Sample Report: https://www.datamintelligence.com/download-sample/cell-therapy-market

Cell Therapy Market Key Drivers:
• Rising Prevalence of Chronic and Degenerative Diseases
An increasing global burden of conditions such as cancer, autoimmune disorders, and neurodegenerative diseases is pushing demand for advanced, personalized treatments like cell therapy.

• Advancements in Stem Cell Research and Gene Editing
Breakthroughs in CRISPR technology, induced pluripotent stem cells (iPSCs), and improved cell delivery mechanisms are accelerating the development of safer and more effective therapies.

• Expanding Pipeline of Clinical Trials
A growing number of clinical trials, especially in oncology and immunology, is fueling innovation and helping to establish new treatment standards across various indications.

• Favorable Regulatory Frameworks and Fast-Track Approvals
Regulatory bodies in the U.S., Europe, and Asia are increasingly introducing expedited pathways for regenerative therapies, boosting the time-to-market for novel products.

• Growing Investments and Strategic Collaborations
Public and private sector funding, alongside strategic alliances between biotech firms, academic institutions, and pharmaceutical companies, are enhancing research capabilities and commercialization efforts.

• Personalized Medicine and Precision Therapies
The shift toward individualized treatment approaches is boosting the demand for autologous and allogeneic cell-based therapies that can target specific patient populations.

Market Segments:
• By Source (Autologous, Allogenic)
• By Cell Type (Stem Cells, Non-Stem Cells)
• By Application (Oncology, GIT Conditions, Musculoskeletal Conditions, Immunodeficiency Disorders, Graft-versus-host disease (GVHD), Others)

Ask For Customized Report as per Your Business Requirement: https://www.datamintelligence.com/customize/cell-therapy-market

Cell Therapy Market Geographical Share:
The global cell therapy market is experiencing widespread growth, with key contributions from regions such as North America, Europe, and the Asia-Pacific.
• North America holds the largest share of the market, driven by strong healthcare infrastructure, early adoption of advanced therapies, and significant investment in R&D. The United States, in particular, remains a hub for clinical trials and regulatory approvals of novel cell-based treatments.
• Europe follows closely, supported by active academic research, government initiatives, and increasing commercialization of regenerative therapies. Countries like Germany, the UK, and France are at the forefront of cell therapy innovations.
• Asia-Pacific is emerging as a fast-growing region due to rising healthcare expenditure, expanding biotechnology sectors, and supportive regulatory reforms. Nations such as Japan, South Korea, and China are investing heavily in stem cell research and manufacturing capabilities.

Market Key Players:
Key players are Gilead Sciences, Inc., Novartis AG, Vericel Corporation, CO.DON GmbH, Bristol Myers Squibb company., IOVANCE Biotherapeutics, Inc., Dendreon Pharmaceuticals LLC., Enzyvant Therapeutics GmbH., CellTrans., and Gamida Cell Inc.

Request for FREE Trial Access: https://www.datamintelligence.com/reports-subscription

Major M&A & Strategic Acquisitions:
• AbbVie → Capstan Therapeutics: In June 2025, AbbVie agreed to acquire Capstan Therapeutics for up to $2.1 billion, gaining access to CAR‑T programs like CPTX2309 aimed at autoimmune diseases. The move strengthens AbbVie’s pipeline following Humira patent expiry.
• AstraZeneca → EsoBiotec: In March 2025, AstraZeneca inked a deal to acquire Belgian startup EsoBiotec for $425 million upfront, with milestones up to $1 billion. EsoBiotec’s in vivo CAR‑T platform enables direct reprogramming of T cells in the patient, promising scalability and reduced manufacturing complexity.
• Bristol Myers Squibb (BMS) → 2seventy bio: BMS completed a ~$286 million acquisition of its longtime partner 2seventy bio in Q2 2025, thereby gaining full rights to Abecma (ide cel), a BCMA directed CAR T for multiple myeloma.

Strategic Partnerships & Licensing:
• MaxCyte + TG Therapeutics: MaxCyte licensed its Flow Electroporation/ExPERT platform to TG Therapeutics for off-the-shelf CAR T (azer cel) aimed at autoimmune diseases a strategic expansion beyond oncology.
• Gilead/Kite & Cellectis: Gilead’s Kite division partnered with Cellectis to broaden an allogeneic CAR T pipeline targeting lower failure rates, faster readiness, and reduced costs per patient.
• NecstGen + Galapagos NV: NecstGen (a CDMO) began manufacturing CAR T therapies for Galapagos in Europe, supporting decentralized and scalable production for wider patient access.

Related Reports:
Stem Cell Therapy Market
Stem Cell Therapy for Diabetes and Related Conditions Market

Sai Kiran
DataM Intelligence 4Market Research
+1 877-441-4866
Sai.k@datamintelligence.com
Visit us on social media:
LinkedIn
X

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.